A novel bioassay for the determination of neutralizing antibodies to IFN-β1b

Journal of Interferon and Cytokine Research

Volumn 18, Issue 12, 1998, Pages 1025-1030

  Pungor Jr , Erno ^a   Files, James G ^a   Gabe, Jeffrey D ^a   Do, Link T ^a   Foley, Wayne P ^a   Gray, Julia L ^a   Nelson, Jeffrey W ^a   Nestaas, Eirik ^a   Taylor, Jerry L ^b   Grossberg, Sidney E ^b  

^a BAYER AG   (Germany)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; BIOASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; GENE INDUCTION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 2442743850     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.1025     Document Type: Article

References (15)

1. VALLBRACHT, A., TREUNER, J., FLEHMIG, B., JOESSTER, K.E., and NIETHAMMER, D. (1981). Interferon-neutralizing antibodies in a patient treated with human fibroblast Interferon Nature 289, 496-497.
2. GROSSBERG, S.E., and SEDMAK, J.J. (1984). Assays of interferons. In: Interferon. Volume 1. General and Applied Aspects. A. Billiau (ed.) Amsterdam, The Netherlands: Elsevier Science Publishers B.V., pp. 189-216.
3. THE IFN-β MULTIPLE SCLEROSIS STUDY GROUP. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 43, 655-661.
4. THE IFN-β MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP. (1995). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45, 1277-1285.
5. FILES, J.G., GRAY, J.L., DO, LT., FOLEY, W.P., GABE, J.D., NESTAAS, E., and PUNGOR, E., JR. (1998). A novel sensitive and selective bioassay for human type I interferons. J. Interferon Cytokine Res. 18, 1019-1024.
6. LAROCCA, A.P., LEUNG, S.C., and MARCUS, S.G. (1989). Evaluation of neutralizing antibodies in patients treated with recombinant interferon, Betaseron. J. Interferon Res. 9(Suppl. 1), 51-60.
7. KAWADE, Y. (1986). Quantitation of neutralization of interferon by antibody. Methods Enzymol. 119, 558-573.
8. Research Reference Reagent Note No. 45. (1995). Freeze-dried human antihuman interferon-beta antibody reference Catalog Number G038-501-572. Research resources Section, National Institute of Allergy and Infectious Diseases. Bethesda, MD: NIH.
9. GROSSBERG, S.E., TAYLOR, J.L., SIEBENLIST, R.E., and JAMESON, P. (1986). Biological and immunological assays of human interferons. In: Manual of Clinical Immunology, 3rd ed. N.R. Rose, H. Friedman, and J.L. Fahley (eds.) Washington, DC: American Society of Microbiology Publishing, pp. 295-299.
10. GROSSBERG, S.E., and KAWADE, Y. (1997). The expression of potency of neutralizing antibodies for interferons and other cytokines. Biotherapy 10, 93-98.
11. CODING, J.W. (1978). Use of a staphylococcal protein A as an immunological reagent. J. Irnmunol. Methods 20, 241-249.
12. GROSSBERG, S.E. (1990). Human antibody development to therapeutic response modifiers. In: Progress in Oncology, Update on Cytokines. E. C. Borden (ed.) London: Mediscript, pp. 17-23.
13. FIERLBECK, G., SCHREINER, T., SCHABER, B., WALSER, A., and RASSNER, G. (1994). Neutralizing interferon β antibodies in melanoma patients treated with recombinant and natural interferon β. Cancer Immunol. Immunother. 39, 263-268.
14. FIERLBECK, G., and SCHREINER, T. (1994). Incidence and clinical significance of therapy induced neutralizing antibodies against interferon-β. J. Interferon Res. 14, 205-206.
15. JACOBS, L., COOKFAIR, D., RUDICK, R., HERNDON, R., SALAZAR, A., RICHERT, J., FISCHER, J., GOODKIN, D., GRANGER, C., SIMON, J., EMRICH, L., and THE MS COLLABORATIVE RESEARCH GROUP. (1993). A phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis: current status. Ann. Neurol. 34, 310.